How Immunotherapy Has Redefined the Treatment Paradigm of Metastatic or Locally Advanced Muscle-Invasive Urothelial Bladder Carcinoma
In the past decade, the therapeutic arsenal for metastatic bladder cancer has expanded considerably, with the development of immune checkpoint inhibitors (ICIs), antibody-drug conjugates such as enfortumab vedotin, and anti-fibroblast growth factor receptor agents. Clinical trials evaluating ICIs as...
Gespeichert in:
| Veröffentlicht in: | Cancers 2024-05, Vol.16 (9), p.1780 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 9 |
| container_start_page | 1780 |
| container_title | Cancers |
| container_volume | 16 |
| creator | Larroquette, Mathieu Lefort, Félix Domblides, Charlotte Héraudet, Luc Robert, Grégoire Ravaud, Alain Gross-Goupil, Marine |
| description | In the past decade, the therapeutic arsenal for metastatic bladder cancer has expanded considerably, with the development of immune checkpoint inhibitors (ICIs), antibody-drug conjugates such as enfortumab vedotin, and anti-fibroblast growth factor receptor agents. Clinical trials evaluating ICIs as neoadjuvants, adjuvants, or first- or second-line treatments have produced conflicting results. However, first-line therapeutic strategies have been redefined by the recent publication of results from two clinical trials: CheckMate-901, which demonstrated the superiority of combined treatment with nivolumab and chemotherapy in extending overall survival, and EV-302, which demonstrated that combined treatment with pembrolizumab and enfortumab vedotin reduced the risk of death by 53%. In this review, we discuss the role of ICIs, alone or in combination, in bladder cancer management in the metastatic and adjuvant settings in 2024, considering the latest published trials. The potential role of ICIs as neoadjuvants is also discussed. |
| doi_str_mv | 10.3390/cancers16091780 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_04833214v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A793567284</galeid><sourcerecordid>A793567284</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-93ae2129a002e6dc5f84ed4348659641de7962348a0610f816d11a44ee2ce54c3</originalsourceid><addsrcrecordid>eNptkk1v1DAQhiMEotXSMzdkiQsc0vordnJcVsCutBUItedosCetKyde7GTR_gD-Nw5bClTYB9uvnnc8Y09RvGT0XIiGXhgYDMbEFG2YrumT4pRTzUulGvn0r_1JcZbSHc1DCKaVfl6ciFoLqgU_LX6sw3ey6ftpCOMtRtgdyBoS-YIWOzegJVklVxFh7HEYyWeIYN1NT0JHLnGENMLoDAmRbIMB7w9kafdzWpZcTsl4LDfDHpLbI7mO8w3egSfvPFiLkawgGjeEHl4UzzrwCc_u10Vx_eH91Wpdbj993KyW29JIzsayEYCc8QYo5aisqbpaopVC1qpqlGQWdaN4PgJVjHY1U5YxkBKRG6ykEYvi7THuLfh2F10P8dAGcO16uW1njcpaCM7knmX2zZHdxfBtwjS2vUsGvYcBw5RaQSvR6Jrlp1wUrx-hd2GKQ67kF8W40LT5Q92Ax9YNXRgjmDlou9SNqJTmtczU-X-oPC32zoQhf0vW_zFcHA0mhpQidg-FMdrOfdI-6pPseHWf7vS1R_vA_-4K8RPJULc8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3053123709</pqid></control><display><type>article</type><title>How Immunotherapy Has Redefined the Treatment Paradigm of Metastatic or Locally Advanced Muscle-Invasive Urothelial Bladder Carcinoma</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Larroquette, Mathieu ; Lefort, Félix ; Domblides, Charlotte ; Héraudet, Luc ; Robert, Grégoire ; Ravaud, Alain ; Gross-Goupil, Marine</creator><creatorcontrib>Larroquette, Mathieu ; Lefort, Félix ; Domblides, Charlotte ; Héraudet, Luc ; Robert, Grégoire ; Ravaud, Alain ; Gross-Goupil, Marine</creatorcontrib><description>In the past decade, the therapeutic arsenal for metastatic bladder cancer has expanded considerably, with the development of immune checkpoint inhibitors (ICIs), antibody-drug conjugates such as enfortumab vedotin, and anti-fibroblast growth factor receptor agents. Clinical trials evaluating ICIs as neoadjuvants, adjuvants, or first- or second-line treatments have produced conflicting results. However, first-line therapeutic strategies have been redefined by the recent publication of results from two clinical trials: CheckMate-901, which demonstrated the superiority of combined treatment with nivolumab and chemotherapy in extending overall survival, and EV-302, which demonstrated that combined treatment with pembrolizumab and enfortumab vedotin reduced the risk of death by 53%. In this review, we discuss the role of ICIs, alone or in combination, in bladder cancer management in the metastatic and adjuvant settings in 2024, considering the latest published trials. The potential role of ICIs as neoadjuvants is also discussed.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers16091780</identifier><identifier>PMID: 38730732</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Adjuvants ; Biochemistry, Molecular Biology ; Biological products ; Bladder ; Bladder cancer ; Cancer ; Carcinoma ; Care and treatment ; Chemotherapy ; Cisplatin ; Clinical trials ; Disease management ; FDA approval ; Immune checkpoint inhibitors ; Immunotherapy ; Life Sciences ; Ligands ; Metastases ; Metastasis ; Molecular biology ; Monoclonal antibodies ; Patients ; Pembrolizumab ; Prognosis ; Response rates ; Survival ; Tumors ; Urothelial carcinoma</subject><ispartof>Cancers, 2024-05, Vol.16 (9), p.1780</ispartof><rights>COPYRIGHT 2024 MDPI AG</rights><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Attribution</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c421t-93ae2129a002e6dc5f84ed4348659641de7962348a0610f816d11a44ee2ce54c3</cites><orcidid>0000-0002-0676-7945 ; 0000-0002-9455-0657 ; 0000-0001-5249-8689 ; 0000-0002-3176-4076 ; 0000-0001-7963-3887</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38730732$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://cnrs.hal.science/hal-04833214$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Larroquette, Mathieu</creatorcontrib><creatorcontrib>Lefort, Félix</creatorcontrib><creatorcontrib>Domblides, Charlotte</creatorcontrib><creatorcontrib>Héraudet, Luc</creatorcontrib><creatorcontrib>Robert, Grégoire</creatorcontrib><creatorcontrib>Ravaud, Alain</creatorcontrib><creatorcontrib>Gross-Goupil, Marine</creatorcontrib><title>How Immunotherapy Has Redefined the Treatment Paradigm of Metastatic or Locally Advanced Muscle-Invasive Urothelial Bladder Carcinoma</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>In the past decade, the therapeutic arsenal for metastatic bladder cancer has expanded considerably, with the development of immune checkpoint inhibitors (ICIs), antibody-drug conjugates such as enfortumab vedotin, and anti-fibroblast growth factor receptor agents. Clinical trials evaluating ICIs as neoadjuvants, adjuvants, or first- or second-line treatments have produced conflicting results. However, first-line therapeutic strategies have been redefined by the recent publication of results from two clinical trials: CheckMate-901, which demonstrated the superiority of combined treatment with nivolumab and chemotherapy in extending overall survival, and EV-302, which demonstrated that combined treatment with pembrolizumab and enfortumab vedotin reduced the risk of death by 53%. In this review, we discuss the role of ICIs, alone or in combination, in bladder cancer management in the metastatic and adjuvant settings in 2024, considering the latest published trials. The potential role of ICIs as neoadjuvants is also discussed.</description><subject>Adjuvants</subject><subject>Biochemistry, Molecular Biology</subject><subject>Biological products</subject><subject>Bladder</subject><subject>Bladder cancer</subject><subject>Cancer</subject><subject>Carcinoma</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Cisplatin</subject><subject>Clinical trials</subject><subject>Disease management</subject><subject>FDA approval</subject><subject>Immune checkpoint inhibitors</subject><subject>Immunotherapy</subject><subject>Life Sciences</subject><subject>Ligands</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Molecular biology</subject><subject>Monoclonal antibodies</subject><subject>Patients</subject><subject>Pembrolizumab</subject><subject>Prognosis</subject><subject>Response rates</subject><subject>Survival</subject><subject>Tumors</subject><subject>Urothelial carcinoma</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkk1v1DAQhiMEotXSMzdkiQsc0vordnJcVsCutBUItedosCetKyde7GTR_gD-Nw5bClTYB9uvnnc8Y09RvGT0XIiGXhgYDMbEFG2YrumT4pRTzUulGvn0r_1JcZbSHc1DCKaVfl6ciFoLqgU_LX6sw3ey6ftpCOMtRtgdyBoS-YIWOzegJVklVxFh7HEYyWeIYN1NT0JHLnGENMLoDAmRbIMB7w9kafdzWpZcTsl4LDfDHpLbI7mO8w3egSfvPFiLkawgGjeEHl4UzzrwCc_u10Vx_eH91Wpdbj993KyW29JIzsayEYCc8QYo5aisqbpaopVC1qpqlGQWdaN4PgJVjHY1U5YxkBKRG6ykEYvi7THuLfh2F10P8dAGcO16uW1njcpaCM7knmX2zZHdxfBtwjS2vUsGvYcBw5RaQSvR6Jrlp1wUrx-hd2GKQ67kF8W40LT5Q92Ax9YNXRgjmDlou9SNqJTmtczU-X-oPC32zoQhf0vW_zFcHA0mhpQidg-FMdrOfdI-6pPseHWf7vS1R_vA_-4K8RPJULc8</recordid><startdate>20240501</startdate><enddate>20240501</enddate><creator>Larroquette, Mathieu</creator><creator>Lefort, Félix</creator><creator>Domblides, Charlotte</creator><creator>Héraudet, Luc</creator><creator>Robert, Grégoire</creator><creator>Ravaud, Alain</creator><creator>Gross-Goupil, Marine</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><orcidid>https://orcid.org/0000-0002-0676-7945</orcidid><orcidid>https://orcid.org/0000-0002-9455-0657</orcidid><orcidid>https://orcid.org/0000-0001-5249-8689</orcidid><orcidid>https://orcid.org/0000-0002-3176-4076</orcidid><orcidid>https://orcid.org/0000-0001-7963-3887</orcidid></search><sort><creationdate>20240501</creationdate><title>How Immunotherapy Has Redefined the Treatment Paradigm of Metastatic or Locally Advanced Muscle-Invasive Urothelial Bladder Carcinoma</title><author>Larroquette, Mathieu ; Lefort, Félix ; Domblides, Charlotte ; Héraudet, Luc ; Robert, Grégoire ; Ravaud, Alain ; Gross-Goupil, Marine</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-93ae2129a002e6dc5f84ed4348659641de7962348a0610f816d11a44ee2ce54c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adjuvants</topic><topic>Biochemistry, Molecular Biology</topic><topic>Biological products</topic><topic>Bladder</topic><topic>Bladder cancer</topic><topic>Cancer</topic><topic>Carcinoma</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Cisplatin</topic><topic>Clinical trials</topic><topic>Disease management</topic><topic>FDA approval</topic><topic>Immune checkpoint inhibitors</topic><topic>Immunotherapy</topic><topic>Life Sciences</topic><topic>Ligands</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Molecular biology</topic><topic>Monoclonal antibodies</topic><topic>Patients</topic><topic>Pembrolizumab</topic><topic>Prognosis</topic><topic>Response rates</topic><topic>Survival</topic><topic>Tumors</topic><topic>Urothelial carcinoma</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Larroquette, Mathieu</creatorcontrib><creatorcontrib>Lefort, Félix</creatorcontrib><creatorcontrib>Domblides, Charlotte</creatorcontrib><creatorcontrib>Héraudet, Luc</creatorcontrib><creatorcontrib>Robert, Grégoire</creatorcontrib><creatorcontrib>Ravaud, Alain</creatorcontrib><creatorcontrib>Gross-Goupil, Marine</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Larroquette, Mathieu</au><au>Lefort, Félix</au><au>Domblides, Charlotte</au><au>Héraudet, Luc</au><au>Robert, Grégoire</au><au>Ravaud, Alain</au><au>Gross-Goupil, Marine</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>How Immunotherapy Has Redefined the Treatment Paradigm of Metastatic or Locally Advanced Muscle-Invasive Urothelial Bladder Carcinoma</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2024-05-01</date><risdate>2024</risdate><volume>16</volume><issue>9</issue><spage>1780</spage><pages>1780-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>In the past decade, the therapeutic arsenal for metastatic bladder cancer has expanded considerably, with the development of immune checkpoint inhibitors (ICIs), antibody-drug conjugates such as enfortumab vedotin, and anti-fibroblast growth factor receptor agents. Clinical trials evaluating ICIs as neoadjuvants, adjuvants, or first- or second-line treatments have produced conflicting results. However, first-line therapeutic strategies have been redefined by the recent publication of results from two clinical trials: CheckMate-901, which demonstrated the superiority of combined treatment with nivolumab and chemotherapy in extending overall survival, and EV-302, which demonstrated that combined treatment with pembrolizumab and enfortumab vedotin reduced the risk of death by 53%. In this review, we discuss the role of ICIs, alone or in combination, in bladder cancer management in the metastatic and adjuvant settings in 2024, considering the latest published trials. The potential role of ICIs as neoadjuvants is also discussed.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>38730732</pmid><doi>10.3390/cancers16091780</doi><orcidid>https://orcid.org/0000-0002-0676-7945</orcidid><orcidid>https://orcid.org/0000-0002-9455-0657</orcidid><orcidid>https://orcid.org/0000-0001-5249-8689</orcidid><orcidid>https://orcid.org/0000-0002-3176-4076</orcidid><orcidid>https://orcid.org/0000-0001-7963-3887</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2024-05, Vol.16 (9), p.1780 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_04833214v1 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access |
| subjects | Adjuvants Biochemistry, Molecular Biology Biological products Bladder Bladder cancer Cancer Carcinoma Care and treatment Chemotherapy Cisplatin Clinical trials Disease management FDA approval Immune checkpoint inhibitors Immunotherapy Life Sciences Ligands Metastases Metastasis Molecular biology Monoclonal antibodies Patients Pembrolizumab Prognosis Response rates Survival Tumors Urothelial carcinoma |
| title | How Immunotherapy Has Redefined the Treatment Paradigm of Metastatic or Locally Advanced Muscle-Invasive Urothelial Bladder Carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T07%3A41%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=How%20Immunotherapy%20Has%20Redefined%20the%20Treatment%20Paradigm%20of%20Metastatic%20or%20Locally%20Advanced%20Muscle-Invasive%20Urothelial%20Bladder%20Carcinoma&rft.jtitle=Cancers&rft.au=Larroquette,%20Mathieu&rft.date=2024-05-01&rft.volume=16&rft.issue=9&rft.spage=1780&rft.pages=1780-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers16091780&rft_dat=%3Cgale_hal_p%3EA793567284%3C/gale_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3053123709&rft_id=info:pmid/38730732&rft_galeid=A793567284&rfr_iscdi=true |